source
- Vor Bio pays RemeGen $10 million for rights to long-acting autoimmune drug candidate RC298Vor Bio announced a licensing agreement with RemeGen, paying $10 million upfront in cash and issuing warrants valued at about $46 million for rights to RC298 outside Greater China. RC298 is a long…
- Biopharma job postings rise 31% YoY in Q3 while layoffs plunge 90%The third‑quarter 2026 job market report shows a strong rebound in biopharma hiring. Live job listings on BioSpace were up 31% compared with the same period last year, marking the biggest year‑over…